M&A Analysis: M&A Rises In 2017 As Market Set To Bounce Back In 2018
Executive Summary
2017 proved to be a busy year for medtech M&A activity, with the number of deals rising from 174 in 2016, to 206 in 2017. The year also brought a number of notable acquisitions, including Becton Dickinson's blockbuster $24bn purchase of CR Bard and Dutch health-care giant Philips undertaking an ambitious acquisition spree. Medtech Insight takes a look at the highlights of 2017 and what's in store for 2018.
You may also be interested in...
Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis
As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.
US Approvals Analysis: Hits Just Keep On Coming. Can It Last?
2017 was another record year for novel device approvals in the US, with typical large numbers of cardiovascular and IVD go-aheads, along with notable successes in neurology, with noninvasive stimulation and digital-app solutions seeing success. There was also an increase in 510(k) clearances last year. Here's a look at some key FDA approvals and clearance trends from the past year, including in infographic form.
Philips Grows Image-Guided Intervention Focus With Spectranetics Buy
In its second acquisition this month and fourth this year, Philips is buying US device maker Spectranetics Corp. for about $2bn to add laser atherectomy catheters to its vascular imaging line-up.